Table 1.

Clinical data of patients with GBM treated with bevacizumab

Patient IDSexAge at tumor resection (years)MGMT statusDuration of BEV treatment (days)Termination of BEV treatment prior to recurrent tumor resection (days)Age at resection of recurrent tumor (years)PD-L1 expression pre/post-BEV
1n.a.50n.a.n.a.n.a.n.a.++/+++++
2F46U1709646−/+
3F70U2583471−/++++
4M43U1403143−/+
5F62U21016963−/−
6M51U9117951−/−
7M30U40720431−/−
8M52U843552−/+
9M49M160n.a.49.−/−
10F41Un.a.n.a.n.a.−/−
11M56n.a.2884557+/+
12M38Mn.a.n.a.n.a.−/−
13M55Un.a.150n.a.−/+
14F72U2640373+/+++++
15F63U2803364−/+
16M47U21413348−/−
17M45n.a.n.a.n.a.n.a.−/−
18M49n.a.843250−/−
19M41M2172342−/−
20M47n.a.n.a.n.a.n.a.−/+
21F46n.a.n.a.n.a.n.a.−/−
22n.a.65n.a.n.a.n.a.n.a.−/++
23F41n.a.n.a.n.a.n.a.−/−
24Mn.a.n.a.n.a.n.a.n.a.−/−
25F45U2813446−/−
26M65n.a.623665−/−
27F66M293067−/−
28M53n.a.1142753−/−
29F62n.a.n.a.n.a.n.a.−/−
30M51U903051−/−
  • NOTE: Scoring, < 6,5 MFI, no PD-L1 expression (−); 6,5–24,99 MFI, PD-L1 expression (+ to ++++); ≥ 25 MFI, high PD-L1 expression (+++++); MFI, mean fluorescence intensity/100 cells.

  • Abbreviations: BEV, bevacizumab; F, female; M, male; M, methylated; MGMT, O6-Methylguanine-DNA-Methyltransferase; n.a., not available; U, unmethylated.